Timigutuzumab (Anti-ERBB2 / HER2 / CD340) is a humanized immunoglobulin that targets the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2, also known as HER2). Timigutuzumab can be used for cancer research. MW: 150 KD.